Thursday, March 10, 2016 4:00:34 PM
First, a breakdown of warrants and their exercise prices:
A & A-1: $0.10
B & B-1: $0.20
C & C-1: $0.50
D & D-1: $0.75
E & E-1: $1.25
Let’s start with the warrants issued to Eastern Capital as these are a non-issue and should cause no downward pressure on share price.
This is what they were issued (After the restructuring agreement):
Stock: 5,000,000 shares
Series A-1: 5,000,000
Series B-1: 10,000,000
Series C-1: 10,000,000
Series D-1: 5,000,000
Series E-1: 5,000,000
This is what they currently claim to own on their most current 13G/A: http://archive.fast-edgar.com/20150929/AQZZE22C6222F2Z2222S22ZZ7V9FZ2KH6G72
Stock: 20,000,000 shares
Series A-1: 5,000,000
Series B-1: 0
Series C-1: 5,000,000
Series D-1: 5,000,000
Series E-1: 5,000,000
Everything here adds up. They have exercised all of their Series B-1s and half their Series C-1s when added with the 5,000,000 shares they were issued at first unit purchase is 20,000,000. They have not dumped any shares as they are restricted and CANNOT be dumped very easily even if Eastern wanted to. This is in accordance with SEC rule 144 which states that an entity my not sell control or restricted shares in an amount greater than 1% of outstanding shares of the same class in any 3 month period. So with outstanding shares of about 64 mil he will only be able to sell 640,000 in any given 3 month period. Even if he chooses to do this it certainly won’t harm the share price.
SEC Rule 144https://www.sec.gov/investor/pubs/rule144.htm
Next we will break down the rest of the warrant which is a bit cloudy but in the end it makes good enough sense to me. I will break these down by who they were issued to which reveals who our main culprits are when it comes to dumping shares. The warrants were initially issued to American Capital, Empery Asset Management, Brio Capital Master Fund, & Iroquois Capital Management. There were also some issued to 4 trust accounts managed by Richard Abbe who is managing partner at Iroquois, I have lumped them together and from here on out I will refer to them as the Abbe Trusts. Also when I say originally issued this is after the restructure, just to be clear.
American Capital
Originally issued:
Stock: 750,000 shares
Series A: 750,000
Series B: 1,500,000
Series C: 1,500,000
Series D: 750,000
Series E: 750,000
This is what they currently claim to own on their most current 13G/A: http://www.sec.gov/Archives/edgar/data/1094038/000114420415016463/v404523_sc13g.htm
Stock: 1,500,000 shares
Series A: 750,000
Series B: 0
Series C: 1,500,000
Series D: 750,000
Series E: 750,000
Iroquois Capital Management
Originally Issued:
Stock: 1,250,000 shares
Series A: 1,250,000
Series B: 2,500,000
Series C: 2,500,000
Series D: 1,250,000
Series E: 1,250,000
This is what they currently claim to own on their most current 13G/A: http://www.sec.gov/Archives/edgar/data/1094038/000093041316005298/c83897_sc13ga.htm
Stock: 2,231,124 shares
Series A: 1,250,000
Series B: 0
Series C: 2,500,000
Series D: 1,250,000
Series E: 1,250,000
Abbe Trusts
Originally Issued:
Stock: 499,995 shares
Series A: 499,995
Series B: 999,990
Series C: 999,990
Series D: 499,995
Series E: 499,995
This is what they currently claim to own on Iroquois’ most current 13G/A under Richard Abbe Sole power: http://www.sec.gov/Archives/edgar/data/1094038/000093041316005298/c83897_sc13ga.htm
Stock: 499,995 shares
Series A: 250,000
Series B: 0
Series C: 499,995
Series D: 499,995
Series E: 499,995
OK, here comes the cloudy part. The following two entities do not claim to have any Series A, D, or E warrants on their most recent 13G/A filings. I have decided to assume that they exercised their A warrants and still hold their D & E warrants as these are currently not at exercise price. The price was in range of the D warrants but since they have not exercised enough C warrants they therefore cannot exercise any D warrants. Like I said in the beginning the math will eventually make sense.
Empery Asset Management
Originally Issued:
Stock: 2,320,000 shares
Series A: 2,320,000
Series B: 4,640,000
Series C: 4,640,000
Series D: 2,320,000
Series E: 2,320,000
This is what they currently claim to own on their most current 13G/A: http://www.sec.gov/Archives/edgar/data/1094038/000090266416004887/p16-0110sc13ga.htm
Stock: 757,000 shares
Series A: 0
Series B: 0
Series C: 2,320,000
Series D: 2,320,000
Series E: 2,320,000
Brio Capital Master Fund
Originally Issued:
Stock: 2,500,000 shares
Series A: 2,500,000
Series B: 5,000,000
Series C: 5,000,000
Series D: 2,500,000
Series E: 2,500,000
This is what they currently claim to own on their most current 13G/A: http://www.sec.gov/Archives/edgar/data/1094038/000121390016010454/sc13g0116a1briocapital_tapim.htm
Stock: 0 shares
Series A: 0
Series B: 0
Series C: 4,711,239
Series D: 2,320,000
Series E: 2,320,000
Now for the fun part. Let’s find out who has been screwing us all over. In the following, total shares owned will refer to the amount of shares each entity would have if they did not dump any shares obtained from warrant conversion. This will also include the shares they obtain upon purchasing the units from the company. Each unit included 1 share of stock and 1 A, B, C, D, & E warrant.
Eastern Capital
Total Shares Owned: 20,000,000
Current Shares Owned: 20,000,000
Dumped: 0
American Capital
Total Shares Owned: 2,250,000
Current Shares Owned: 1,500,000
Dumped: 750,000
Iroquois Capital Management
Total Shares Owned: 3,750,000
Current Shares Owned: 2,231,124
Dumped: 1,518,876
Abbe Trusts
Total Shares Owned: 1,249,985
Current Shares Owned: 979,990
Dumped: 269,995
Empery Asset Management
Total Shares Owned: 9,280,000
Current Shares Owned: 757,000
Dumped: 8,523,000
Brio Capital Master Fund
Total Shares Owned: 10,288,761
Current Shares Owned: 0
Dumped: 10,288,761
So as we can see Brio Capital has been the biggest culprit literally dumping every share they have come in possession of. Followed by Empery and then Iroquois.
In total here is what is left of each warrant class:
A-1: 5,000,000
B-1: 0
C-1: 5,000,000
D-1: 5,000,000
E-1: 5,000,000
To stress again the above were all issued to Eastern Capital and are a non-issue as they CANNOT dump these very easily upon conversion. Again, SEC Rule 144 https://www.sec.gov/investor/pubs/rule144.htm
A: 2,250,000
B: 0
C: 11,031,239
D: 7,319,995
E: 7,319,995
I would expect us to close in on at least $1.00 before any more are exercised as most of these entities have been systematic in their exercising of these warrants only exercising them well above their exercise prices. With any substantial news that we are all expecting what warrants we have left to worry about should be quickly absorbed with only minor share price suppression, if any.
I hope this helps anyone who was curious on the current warrant situation.
Below are two links to my original DD post and my follow up to the original.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118740621
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119149223
Friends don't let friends place market orders
Recent MRKR News
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 11:22:44 AM
- Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program • GlobeNewswire Inc. • 08/07/2023 11:00:17 AM
- Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023 • GlobeNewswire Inc. • 07/26/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2023 11:09:50 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM